View Financial HealthLadRx 배당 및 자사주 매입배당 기준 점검 0/6LadRx 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률n/a자사주 매입 수익률총 주주 수익률n/a미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Apr 16LadRx Corporation Announces Resignation of Joel Caldwell from the Board of Directors and All Board Committees, Effective as of April 15, 2025LadRx Corporation announced on April 14, 2025, Joel Caldwell tendered his resignation from the board of directors of the company and all Board committees thereto, effective as of April 15, 2025. Mr. Caldwell’s resignation was not in connection with any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.공시 • Aug 21LadRx Corporation, Annual General Meeting, Oct 04, 2024LadRx Corporation, Annual General Meeting, Oct 04, 2024. Location: 11726 san vicente blvd, suite 650, ca 90049, los angeles United States공시 • Jul 29LadRx Corporation, Annual General Meeting, Sep 06, 2023LadRx Corporation, Annual General Meeting, Sep 06, 2023, at 10:00 Pacific Daylight. Location: 11726 San Vicente Boulevard, Suite 650, Los Angeles California United States Agenda: To consider the election of one Class II director to serve until the 2026 Annual Meeting of Stockholders; to consider the approval to amend the Company’s governing documents (Restated Certificate of Incorporation and By-Laws) to declassify the structure of the Board, such that each director standing for election shall only be eligible to be elected for one-year terms; to consider the ratification of the appointment of Weinberg & Company as company's independent registered public accounting firm for the fiscal year ending December 31, 2023; to consider the approval, on an advisory basis, the compensation of company's named executive officers as disclosed in this Proxy Statement; to consider the approval, on an advisory, basis, regarding the frequency of future stockholder advisory votes to approve the compensation of company's named executive officers; and to consider other matters.공시 • Oct 08CytRx Corporation Highlights Use of Licensed Drug Aldoxorubicin in Treatment of Former Senate Majority Leader Harry Reid’S Pancreatic CancerCytRx Corporation announced that it has highlighted the use of its licensed drug – aldoxorubicin – in the combination immunotherapy used by ImmunityBio Inc. and NantKwest Inc. to treat former Senate Majority Leader Harry Reid’s stage IV pancreatic cancer. It was widely reported in June 2020 that former Senator Reid described himself as being in “complete remission” after receiving experimental treatment pioneered by the Chief Executive Officer of ImmunityBio and NantKwest.공시 • Sep 30Cytrx Corporation, Advanced Bioscience Laboratories and University of Massachusetts Announce First Patients Enrolled in Hiv Vaccine TrialCytRx Corp. Advanced BioScience Laboratories (ABL) and the University of Massachusetts Medical School (UMMS) announced that investigators have enrolled and inoculated the first patients in the Phase I trial for an experimental HIV vaccine developed by the University of Massachusetts Medical School and ABL and supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. The clinical trial, whose primary objective is to determine the safety and tolerability of the multiple dosing levels of the polyvalent vaccine. The trial will enroll 36 people who do not have HIV. The vaccine contains only portions of the HIV genome and, therefore, individuals receiving inoculations cannot get HIV from the vaccine. Volunteers' given the DNA and protein boost vaccine, will be carefully monitored for any adverse effects, and will also have samples collected in order to measure immune responses over time.공시 • Sep 18CytRx Corporation Highlights Orphazyme’s Receipt of FDA Acceptance and Priority Review of its New Drug Application for arimoclomol for Niemann-Pick disease Type CCytRx Corporation highlighted that Orphayzme A/S (“Orphazyme”) announced that the U.S. Food and Drug Administration (“FDA”) has accepted, with Priority Review, the company’s New Drug Application (“NDA”) for arimoclomol for the treatment of Niemann-Pick disease Type C (“NPC”). The FDA grants Priority Review to applications for potential therapies that, if approved, could offer a significant improvement in safety, effectiveness, diagnosis or prevention of serious conditions. This designation shortens the review period from the standard 10 months to 6 months from the acceptance of the NDA. The FDA has set a target action date of March 17, 2021 under the Prescription Drug User Fee Act (“PDUFA”) and has indicated that it does not currently plan to hold an advisory committee meeting to discuss the application. Arimoclomol was previously granted FDA Fast Track and Breakthrough Therapy Designations for NPC, as well as Orphan Drug and Rare Pediatric Disease Designations. Orphazyme expects to file a Marketing Authorisation Application with the European Medicines Agency for arimoclomol in NPC in H2 2020.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 LADX 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: LADX 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장LadRx 배당 수익률 vs 시장LADX의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (LADX)n/a시장 하위 25% (US)1.4%시장 상위 25% (US)4.2%업계 평균 (Biotechs)2.4%분석가 예측 (LADX) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 LADX 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 LADX 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 LADX 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: LADX 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YUS 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/27 01:01종가2026/05/19 00:00수익2025/03/31연간 수익2024/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스LadRx Corporation는 8명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Ashok KumarAegis Capital CorporationMorris AjzenmanGriffin SecuritiesAndrew FeinH.C. Wainwright & Co.5명의 분석가 더 보기
공시 • Apr 16LadRx Corporation Announces Resignation of Joel Caldwell from the Board of Directors and All Board Committees, Effective as of April 15, 2025LadRx Corporation announced on April 14, 2025, Joel Caldwell tendered his resignation from the board of directors of the company and all Board committees thereto, effective as of April 15, 2025. Mr. Caldwell’s resignation was not in connection with any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.
공시 • Aug 21LadRx Corporation, Annual General Meeting, Oct 04, 2024LadRx Corporation, Annual General Meeting, Oct 04, 2024. Location: 11726 san vicente blvd, suite 650, ca 90049, los angeles United States
공시 • Jul 29LadRx Corporation, Annual General Meeting, Sep 06, 2023LadRx Corporation, Annual General Meeting, Sep 06, 2023, at 10:00 Pacific Daylight. Location: 11726 San Vicente Boulevard, Suite 650, Los Angeles California United States Agenda: To consider the election of one Class II director to serve until the 2026 Annual Meeting of Stockholders; to consider the approval to amend the Company’s governing documents (Restated Certificate of Incorporation and By-Laws) to declassify the structure of the Board, such that each director standing for election shall only be eligible to be elected for one-year terms; to consider the ratification of the appointment of Weinberg & Company as company's independent registered public accounting firm for the fiscal year ending December 31, 2023; to consider the approval, on an advisory basis, the compensation of company's named executive officers as disclosed in this Proxy Statement; to consider the approval, on an advisory, basis, regarding the frequency of future stockholder advisory votes to approve the compensation of company's named executive officers; and to consider other matters.
공시 • Oct 08CytRx Corporation Highlights Use of Licensed Drug Aldoxorubicin in Treatment of Former Senate Majority Leader Harry Reid’S Pancreatic CancerCytRx Corporation announced that it has highlighted the use of its licensed drug – aldoxorubicin – in the combination immunotherapy used by ImmunityBio Inc. and NantKwest Inc. to treat former Senate Majority Leader Harry Reid’s stage IV pancreatic cancer. It was widely reported in June 2020 that former Senator Reid described himself as being in “complete remission” after receiving experimental treatment pioneered by the Chief Executive Officer of ImmunityBio and NantKwest.
공시 • Sep 30Cytrx Corporation, Advanced Bioscience Laboratories and University of Massachusetts Announce First Patients Enrolled in Hiv Vaccine TrialCytRx Corp. Advanced BioScience Laboratories (ABL) and the University of Massachusetts Medical School (UMMS) announced that investigators have enrolled and inoculated the first patients in the Phase I trial for an experimental HIV vaccine developed by the University of Massachusetts Medical School and ABL and supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. The clinical trial, whose primary objective is to determine the safety and tolerability of the multiple dosing levels of the polyvalent vaccine. The trial will enroll 36 people who do not have HIV. The vaccine contains only portions of the HIV genome and, therefore, individuals receiving inoculations cannot get HIV from the vaccine. Volunteers' given the DNA and protein boost vaccine, will be carefully monitored for any adverse effects, and will also have samples collected in order to measure immune responses over time.
공시 • Sep 18CytRx Corporation Highlights Orphazyme’s Receipt of FDA Acceptance and Priority Review of its New Drug Application for arimoclomol for Niemann-Pick disease Type CCytRx Corporation highlighted that Orphayzme A/S (“Orphazyme”) announced that the U.S. Food and Drug Administration (“FDA”) has accepted, with Priority Review, the company’s New Drug Application (“NDA”) for arimoclomol for the treatment of Niemann-Pick disease Type C (“NPC”). The FDA grants Priority Review to applications for potential therapies that, if approved, could offer a significant improvement in safety, effectiveness, diagnosis or prevention of serious conditions. This designation shortens the review period from the standard 10 months to 6 months from the acceptance of the NDA. The FDA has set a target action date of March 17, 2021 under the Prescription Drug User Fee Act (“PDUFA”) and has indicated that it does not currently plan to hold an advisory committee meeting to discuss the application. Arimoclomol was previously granted FDA Fast Track and Breakthrough Therapy Designations for NPC, as well as Orphan Drug and Rare Pediatric Disease Designations. Orphazyme expects to file a Marketing Authorisation Application with the European Medicines Agency for arimoclomol in NPC in H2 2020.